COMPASS Pathways Reports Positive 26-Week Phase 3 Data for COMP360 in Treatment-Resistant Depression
CMPS has more than doubled off its 52-week low of $3.24.
Summary
COMPASS Pathways announced positive 26-week Phase 3 clinical trial results for its lead psychedelic therapy, COMP360, for treatment-resistant depression, reinforcing its path to FDA approval and commercial launch.
Key Events · Product Development and Regulatory · CMPS
-
Positive Phase 3 Results
26-week data from the COMP006 trial showed 39% of participants in the 25mg arm achieved a clinically meaningful reduction in depression symptoms (MADRS ≥ 25%) by Week 6, maintaining durability through Week 26.
-
Durable Efficacy & Safety Profile
The results confirm COMP360's rapid onset and durable profile, with a generally well-tolerated and safe profile, consistent with previous studies and no new safety signals identified.
-
Regulatory Progress Confirmed
The data supports the ongoing rolling New Drug Application (NDA) submission to the FDA, which remains on track for final completion in Q4 2026.
-
Anticipated Commercial Launch
The company anticipates a commercial launch of COMP360 in the first half of 2027, subject to FDA approval and DEA rescheduling.
Analysis · CMPS · Life Sciences
This filing provides crucial 26-week results from the COMP006 Phase 3 trial for COMP360, demonstrating rapid onset and durable efficacy in treatment-resistant depression (TRD). The data, which also confirms a favorable safety profile, strengthens the ongoing rolling NDA submission to the FDA and supports the company's anticipated launch in the first half of 2027.
At the time of this filing, CMPS was trading at $12.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $3.24 to $15.40. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.